Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: A prospective analysis study

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages 65-77

  Barnett, Gillian C ^a,c   Coles, Charlotte E ^b   Elliott, Rebecca M ^d   Baynes, Caroline ^c   Luccarini, Craig ^c   Conroy, Don ^c   Wilkinson, Jennifer S ^b   Tyrer, Jonathan ^c   Misra, Vivek ^e   Platte, Radka ^c   Gulliford, Sarah L ^f   Sydes, Matthew R ^g   Hall, Emma ^h   Bentzen, Søren M ⁱ   Dearnaley, David P ^f   Burnet, Neil G ^a,b   Pharoah, Paul DP ^c   Dunning, Alison M ^c   West, Catharine ML ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g MRC CLINICAL TRIALS UNIT   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE P1; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12 RECEPTOR BETA2; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELOPEROXIDASE; ONCOPROTEIN; PROTEIN BAX; PROTEIN ERCC4; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; PROTEIN RAD9; PROTEIN XRCC5; PROTEIN XRCC6; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

ANALYTICAL ERROR; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOLECULAR PATHOLOGY; ONSET AGE; POWER ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION SAFETY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY;

BREAST NEOPLASMS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; LINEAR MODELS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84855321526     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70302-3     Document Type: Article

References (85)

1. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76:S3-S9.
2. Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 2010, 76:S155-S160.
3. Burnet NG, Elliott RM, Dunning A, West CM Radiosensitivity, radiogenomics and RAPPER. Clin Oncol (R Coll Radiol) 2006, 18:525-528.
4. Kerns SL, Ostrer H, Stock R, et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:1292-1300.
5. Bentzen SM Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006, 6:702-713.
6. Alsner J, Andreassen CN, Overgaard J Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008, 18:126-135.
7. Barnett GC, West CM, Dunning AM, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009, 9:134-142.
8. Popanda O, Marquardt JU, Chang-Claude J, Schmezer P Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 2009, 667:58-69.
9. Alsbeih G, El-Sebaie M, Al-Harbi N, Al-Buhairi M, Al-Hadyan K, Al-Rajhi N Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int J Radiat Oncol Biol Phys 2007, 68:229-235.
10. Andreassen CN, Alsner J, Overgaard M, Overgaard J Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003, 69:127-135.
11. Azria D, Ozsahin M, Kramar A, et al. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 2008, 14:6284-6288.
12. De Ruyck K, Van Eijkeren M, Claes K, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005, 62:1140-1149.
13. Isomura M, Oya N, Tachiiri S, et al. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res 2008, 14:6683-6689.
14. Suga T, Iwakawa M, Tsuji H, et al. Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:808-813.
15. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity-modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys 2011, published online Feb 22. 10.1016/j.ijrobp.2010.10.068.
16. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487. on behalf of the RT01 collaborators.
17. Sydes MR, Stephens RJ, Moore AR, et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol 2004, 72:199-211. RT01 collaborators.
18. Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 2010, 77:773-783.
19. Khoo VS, Dearnaley DP Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer-the CHHiP trial. Clin Oncol (R Coll Radiol) 2008, 20:12-14.
20. Gulliford SL, Foo K, Morgan RC, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010, 76:747-754.
21. Mangar SA, Sydes MR, Tucker HL, et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol 2006, 80:355-362.
22. Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 Trial (ISRCTN47772397). Clin Oncol (R Coll Radiol) 2011, 23:613-624.
23. Barnett GC, West CM, Coles CE, et al. Standardized total average toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. Int J Radiat Oncol Biol Phys 2011, published online May 21. 10.1016/j.ijrobp.2011.03.015.
24. Balding DJ A tutorial on statistical methods for population association studies. Nat Rev Genet 2006, 7:781-791.
25. Barnett GC, Wilkinson JS, Moody AM, et al. The Cambridge Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence late toxicity. Clin Oncol (R Coll Radiol) 2011, published online June 4. 10.1016/j.clon.2011.04.011.
26. Bentzen SM, Overgaard J Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol 1994, 4:68-80.
27. Bentzen SM Radiobiological considerations in the design of clinical trials. Radiother Oncol 1994, 32:1-11.
28. Bentzen SM Dose-response relationships in radiotherapy. Basic clinical radiobiology 2009, 56-67. Hodder Arnold, London. M. Joiner, A. van der Kogel (Eds.).
29. Chang-Claude J, Popanda O, Tan XL, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005, 11:4802-4809.
30. Farkasova T, Gurska S, Witkovsky V, Gabelova A Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients; a pilot study. Neoplasma 2008, 55:330-337.
31. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001, 22:917-922.
32. Suga T, Ishikawa A, Kohda M, et al. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:685-693.
33. Fletcher O, Johnson N, dos Santos Silva I, et al. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev 2010, 19:2143-2151. Breast Cancer Association Consortium.
34. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006, 38:873-875.
35. Woodbine L, Grigoriadou S, Goodarzi AA, et al. An Artemis polymorphic variant reduces Artemis activity and confers cellular radiosensitivity. DNA Repair (Amst) 2010, 9:1003-1010.
36. Angèle S, Romestaing P, Moullan N, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 2003, 63:8717-8725.
37. Edvardsen H, Tefre T, Jansen L, et al. Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiation Oncol 2007, 2:25.
38. Ho AY, Fan G, Atencio DP, et al. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69:677-684.
39. Ahn J, Ambrosone CB, Kanetsky PA, et al. Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clin Cancer Res 2006, 12:7063-7070.
40. Gutiérrez-Enríquez S, Fernet M, Dörk T, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 2004, 40:109-119.
41. Kuptsova N, Chang-Claude J, Kropp S, et al. Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer 2008, 122:1333-1339.
42. Au WW, Salama SA, Sierra-Torres CH Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003, 111:1843-1850.
43. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21:551-555.
44. Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 2006, 8:R40.
45. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006, 12:2545-2554.
46. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, et al. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67:1163-1171.
47. Kornguth DG, Garden AS, Zheng Y, Dahlstrom KR, Wei Q, Sturgis EM Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int J Radiat Oncol Biol Phys 2005, 62:665-671.
48. Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 2009, 73:1187-1195.
49. Willems P, Claes K, Baeyens A, et al. Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes Cancer 2008, 47:137-148.
50. Choudhury A, Elliott F, Iles MM, et al. Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Med Genet 2008, 9:69.
51. Girard PM, Kysela B, Harer CJ, Doherty AJ, Jeggo PA Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of two linked polymorphisms. Hum Mol Genet 2004, 13:2369-2376.
52. Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomarkers Prev 2007, 16:2024-2032.
53. Worrillow LJ, Smith AG, Scott K, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008, 45:142-146.
54. Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003, 9:3012-3020.
55. Barnett GC, Coles CE, Burnet NG, et al. No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol 2010, 97:9-14.
56. Burri RJ, Stock RG, Cesaretti JA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 2008, 170:49-59.
57. Giotopoulos G, Symonds RP, Foweraker K, et al. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 2007, 96:1001-1007.
58. Quarmby S, Fakhoury H, Levine E, et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 2003, 79:137-143.
59. Chang-Claude J, Ambrosone CB, Lilla C, et al. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 2009, 100:1680-1686.
60. Tan XL, Popanda O, Ambrosone CB, et al. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 2006, 97:255-262.
61. Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst) 2008, 7:141-148.
62. Aka P, Mateuca R, Buchet JP, Thierens H, Kirsch-Volders M Are genetic polymorphisms in OGG1, XRCC1 and XRCC3 genes predictive for the DNA strand break repair phenotype and genotoxicity in workers exposed to low dose ionising radiations?. Mutat Res 2004, 556:169-181.
63. Godderis L, De Boeck M, Haufroid V, et al. Influence of genetic polymorphisms on biomarkers of exposure and genotoxic effects in styrene-exposed workers. Environ Mol Mutagen 2004, 44:293-303.
64. Vodicka P, Kumar R, Stetina R, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 2004, 25:757-763.
65. Wilding CS, Curwen GB, Tawn EJ, et al. Influence of polymorphisms at loci encoding DNA repair proteins on cancer susceptibility and G2 chromosomal radiosensitivity. Environ Mol Mutagen 2007, 48:48-57.
66. Moullan N, Cox DG, Angèle S, Romestaing P, Gérard JP, Hall J Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003, 12:1168-1174.
67. Severin DM, Leong T, Cassidy B, et al. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys 2001, 50:1323-1331.
68. Brem R, Cox DG, Chapot B, et al. The XRCC1 -77T→C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 2006, 27:2469-2474.
69. Alsbeih G, Torres M, Al-Harbi N, Al-Buhairi M Evidence that individual variations in TP53 and CDKN1A protein responsiveness are related to inherent radiation sensitivity. Radiat Res 2007, 167:58-65.
70. Gao LB, Pan XM, Sun H, et al. The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis. J Exp Clin Cancer Res 2010, 29:117.
71. Bentzen SM, Thames HD, Overgaard M Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single-follow-up clinical study. Radiother Oncol 1989, 15:267-274.
72. Dikomey E, Borgmann K, Peacock J, Jung H Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys 2003, 56:1194-1200.
73. Turesson I Individual variation and dose dependency in the progression rate of skin telangiectasia. Int J Radiat Oncol Biol Phys 1990, 19:1569-1574.
74. Pharoah P How not to interpret a p value?. J Natl Cancer Inst 2007, 99:332-333.
75. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 2007, 3:e42.
76. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009, 41:585-590.
77. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
78. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010, 42:504-507.
79. Wu X, Spitz MR, Amos CI, et al. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res 2006, 66:5993-5996.
80. Borgmann K, Haeberle D, Doerk T, Busjahn A, Stephan G, Dikomey E Genetic determination of chromosomal radiosensitivities in G0- and G2-phase human lymphocytes. Radiother Oncol 2007, 83:196-202.
81. Finnon P, Robertson N, Dziwura S, et al. Evidence for significant heritability of apoptotic and cell cycle responses to ionising radiation. Hum Genet 2008, 123:485-493.
82. Curwen GB, Winther JF, Tawn EJ, et al. G(2) chromosomal radiosensitivity in Danish survivors of childhood and adolescent cancer and their offspring. Br J Cancer 2005, 93:1038-1045.
83. Schmitz A, Bayer J, Dechamps N, Goldin L, Thomas G Heritability of susceptibility to ionizing radiation-induced apoptosis of human lymphocyte subpopulations. Int J Radiat Oncol Biol Phys 2007, 68:1169-1177.
84. West C, Rosenstein BS, Alsner J, et al. Establishment of a radiogenomics consortium. Int J Radiat Oncol Biol Phys 2010, 76:1295-1296.
85. West C, Rosenstein BS Establishment of a radiogenomics consortium. Radiother Oncol 2010, 94:117-118.